Lu-177 DOTATATE + Olaparib in GEP-NETs

Lu-177-DOTATATE in Combination With Olaparib in Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

CLINICALTRIALS.GOV IDENTIFIER:  NCT04086485

DRUG/TREATMENT: Lu-177 DOTATATE + OLAPARIB

PHASE I / II

STATUS:

Recruiting

SPONSOR: 

National Cancer Institute (NCI)

Dr. Del Rivero discusses Lu177-Dotatate + OLAPARIB

DESCRIPTION:

This phase 1-2 trial tests Lu-177-DOTATATE (Lutathera) in combination With olaparib (PARP inhibitor) in inoperable gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). The objective is to learn if people with certain neuroendocrine tumors can take a combination of 2 drugs, Lu-177 DOTATATE and Olaparib, without having severe side effects, and if this treatment makes the tumors shrink.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

PRINCIPAL INVESTIGATOR:

Frank Lin, MD

CONTACT:

National Cancer Institute

Joy Zou, RN

EMAIL: joy.zou@nih.gov

PHONE: 240-760-6153